Jyong Biotech MENS
NASDAQ MENS
$1.66 -0.23 (-12.27%)
As of: Oct 22, 2026 · 3:29 PM EDT

Jyong Biotech (MENS) Operating Leases (2024 - 2025)

Updated

Jyong Biotech's Operating Leases came in at $68,000 for the quarter ended Dec 31, 2025, up 65.9% from $41,000 a year earlier.

Analysis

Jyong Biotech (MENS) Operating Leases (2024 - 2025) Analysis & Trends

  • Going back by year, Operating Leases was $41,000 in the year ended Dec 31, 2024 (+141.2%) and $17,000 in the year ended Dec 31, 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,167.71 Bn 1,136.29 Bn 19.71 Bn
2 Johnson & Johnson 647.75 Bn 567.61 Bn 17.30 Bn
3 AbbVie 503.60 Bn 476.71 Bn 12.70 Bn
4 Merck 368.10 Bn 322.48 Bn 12.21 Bn
5 Novartis Ag 303.19 Bn 267.18 Bn 11.24 Bn
6 Astrazeneca 268.04 Bn 241.73 Bn 12.86 Bn
7 Amgen 242.69 Bn 198.09 Bn 7.24 Bn
8 Gilead Sciences 194.89 Bn 169.09 Bn 6.22 Bn
9 Pfizer 173.31 Bn 119.95 Bn 10.94 Bn
10 Jyong Biotech 121.20 Mn 121.20 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 26,000.00
Jun 30, 2025 628,000.00
Dec 31, 2024 16,000.00
API Access

Jyong Biotech Operating Leases API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=operating-leases&ticker=MENS&period=max&api_key=YOUR_API_KEY